Developing vaccines and treatments for deadly henipaviruses.
Core C - The University of Texas Medical Branch at Galveston
This study is working on new vaccines and treatments for the Hendra and Nipah viruses, which can be very dangerous to people, to help keep everyone safer and healthier.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Henry M. Jackson Fdn for the Adv Mil/med NIH-funded |
| Lab location | 1 site (Bethesda, United States) |
| Project ID | NIH-10581495 on NIH RePORTER |
What this research studies
This research focuses on creating effective vaccines and therapies for Hendra virus (HeV) and Nipah virus (NiV), which are highly lethal pathogens with significant potential for human transmission. The project includes three main approaches: a vaccine based on a soluble form of the HeV glycoprotein, the development of monoclonal antibodies targeting henipaviruses, and the creation of attenuated vaccines. By utilizing these innovative strategies, the research aims to provide preventive and therapeutic options for these dangerous viruses, which currently lack approved treatments. Patients may benefit from advancements in public health and safety as these viruses pose a serious threat to human health.
Who could benefit from this research
Good fit: Ideal candidates for participation or benefit from this research include individuals at risk of exposure to Hendra and Nipah viruses, particularly in outbreak regions.
Not a fit: Patients who are not at risk of exposure to these viruses or who do not live in affected areas may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to effective vaccines and treatments that protect against severe infections caused by Hendra and Nipah viruses.
How similar studies have performed: Previous research has shown promise in developing vaccines and monoclonal antibodies for similar viral pathogens, indicating a potential for success in this area.
Where this research is happening
Bethesda, United States
- Henry M. Jackson Fdn for the Adv Mil/med — Bethesda, United States (Active)
Researchers
- Principal investigator: Geisbert, Thomas William — Henry M. Jackson Fdn for the Adv Mil/med
- Study coordinator: Geisbert, Thomas William
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.